The pharmaceutical industry's blockbuster approach to developing new drugs that created a trillion dollars for shareholders may now be broken.
Based on recent investment levels, success rates and forecasts of commercial performance, Bain expects the current blockbuster drug model to deliver just 5% return on investment - significantly lower than the industry's risk-adjusted cost of capital.
This slide presentation serves as an excellent stand-alone presentation, as well as a valuable supplement to pharmaceutical reports "Best Practices in Global Pharmaceutical Launches" and "Launching Pharmaceutical Megabrands: Best Practices in Marketing Blockbusters," available at http://www3.
Download a summary of "Building Pharmaceutical Blockbusters in Crowded Market" at http://www3.
Pharmaceutical companies are under increasing pressure to generate blockbuster
products because of pricing pressure from managed care, increasing numbers of lower-cost generic alternatives, rising research and development spending and saturated therapeutic categories.
Market outlook: Short-term impact of the departure and arrival of patented blockbusters
on select indications.
Impact of pharmacogenomics: a recent chronology of events and a discussion of the arrival and impact of pharmacogenomic blockbusters
Which drugs now in late-stage development (or recently launched) will be the leading blockbusters
during the next decade?
Global analysis of historical and forecast changes in the blockbuster
market across 12 therapy areas